1-20 of 112
Susanne Saußele
Close
Save search
Sort by
Journal Articles

Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) - an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)

Free
Susanne Isfort, Kirsi Manz, Lino L. Teichmann, Martina Crysandt, Andreas Burchert, Andreas Hochhaus, Susanne Saussele, Alexander Kiani, Joachim R. Goethert, Thomas Illmer, Philippe Schafhausen, Haifa Kathrin Al-Ali, Frank Stegelmann, Mathias Hänel, Tim Pfeiffer, Aristoteles Giagounidis, Georg-Nikolaus Franke, Steffen Koschmieder, Alice Fabarius, Thomas Ernst, Mareille Warnken-Uhlich, Denise Kohn, Markus Pfirrmann, Dominik Wolf, Tim H. H. Brummendorf
Journal: Blood
Blood (2024) 144 (Supplement 1): 1766.
https://doi.org/10.1182/blood-2024-208687
Published: 2024
Journal Articles

Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial ( ECWM-2 ) of the European Consortium for Waldenström's Macroglobulinemia

Free
Christian Buske, Efstathios Kastritis, Alexander Grunenberg, Andreas Viardot, Dajana Kaczynski, Heike Mund, Katja Gutmair, Matthias Zingerle, Paul Duewel, Susanne Saussele, Björn Schöttker, Ullrich Graeven, Martin Dreyling, Andrea Kerkhoff, Thomas Weber, Holger F. Hebart, Ralf Ulrich Trappe, Lisa Kaiser, Elke Runge, Jasmin Mark, Simone Ferrero, Daniela Drandi, Falko Fend, Irina Bonzheim, Eva Hoster, Jens Dreyhaupt, Meletios A. Dimopoulos
Journal: Blood
Blood (2024) 144 (Supplement 1): 859.
https://doi.org/10.1182/blood-2024-200604
Published: 2024
Journal Articles

The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients

Free
Thomas Ernst, Jenny Rinke, Philipp le Coutre, Martina Crysandt, Tim H. H. Brummendorf, Andreas Burchert, Fabian Lang, Susanne Saussele, Markus Pfirrmann, Thomas Lang, Christian Fabisch, Andreas Hochhaus
Journal: Blood
Blood (2024) 144 (Supplement 1): 1774.
https://doi.org/10.1182/blood-2024-193991
Published: 2024
Journal Articles

Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

Free
Andreas Hochhaus, Andreas Burchert, Susanne Saussele, Gabriela M Baerlocher, Jiří Mayer, Tim H. Brümmendorf, Paul La Rosée, Dominik Heim, Stefan W. Krause, Philipp le Coutre, Jenny Rinke, Thoralf Lange, Alice Fabarius, Marcel Lorch, Mathias Hanel, Frank Stegelmann, Georg-Nikolaus Franke, Markus P. Radsak, Volker Kunzmann, Daniela Zackova, Danny Himsel, Denise Kohn, Thomas Lang, Rüdiger Hehlmann, Christian Fabisch, Thomas Ernst, Markus Pfirrmann
Journal: Blood
Blood (2023) 142 (Supplement 1): 446.
https://doi.org/10.1182/blood-2023-182792
Published: 2023
Journal Articles

Benefit of TKI-Treatment in CML after Failing Molecular or Cytogenetic Milestones

Free
Rüdiger Hehlmann, Michael Lauseker, Andreas Hochhaus, Susanne Saussele
Journal: Blood
Blood (2023) 142 (Supplement 1): 4535.
https://doi.org/10.1182/blood-2023-172484
Published: 2023
Journal Articles

ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry

Free
Katharina Kohlbrenner, Norbert Galuschek, Alice Fabarius, Marcel Reiser, Klaus Fenchel, Eva Esseling, Thomas Göhler, Ralf-Bodo Kühn, Reinhard Depenbusch, Ivo Talah Azeh, Erik Engel, Richard Hansen, Mathias Hanel, Paul Jehner, Maisun Abu-Samra, Markus Ritter, Norbert Gattermann, Henning Pelz, Stefan Fuxius, Burkhard Oswald, Gabriela M Baerlocher, Tim H. Brümmendorf, Dominik Heim, Philipp le Coutre, Andreas Burchert, Dietger Niederwieser, Hans Tesch, Wolf-Karsten Hofmann, Andreas Hochhaus, Rüdiger Hehlmann, Susanne Saussele
Journal: Blood
Blood (2023) 142 (Supplement 1): 4539.
https://doi.org/10.1182/blood-2023-180730
Published: 2023
Journal Articles

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Free
Michael Mauro, Yosuke Minami, Andreas Hochhaus, Elza Lomaia, Sergei Voloshin, Anna Turkina, Dong-Wook Kim, Jane F Apperley, Jorge Cortes, Andre N.R. Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P Hughes, Naeem A. Chaudhri, Lynette C.Y. Chee, Valentín García Gutiérrez, Koji Sasaki, Carla Maria Boquimpani De Moura Freitas, Shruti Kapoor, Noemi Espurz, Vishal Dhamal, Delphine Rea
Journal: Blood
Blood (2023) 142 (Supplement 1): 4536.
https://doi.org/10.1182/blood-2023-186854
Published: 2023
Journal Articles

ASC4START and ASC4FIRST: Two Ongoing Phase 3 Trials Investigating Asciminib Monotherapy As First-Line Therapy Versus Tyrosine Kinase Inhibitors in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Free
Andreas Hochhaus, Jorge Cortes, Naoto Takahashi, Richard A. Larson, Ghayas C. Issa, Felice Bombaci, Susanne Saussele, Francois Mahon, Tim H. Brümmendorf, Shruti Kapoor, Tracey McCulloch, Peter Schuld, Timothy P Hughes
Journal: Blood
Blood (2023) 142 (Supplement 1): 6388.
https://doi.org/10.1182/blood-2023-186773
Published: 2023
Journal Articles

Second-Line Ponatinib in Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients Failing or Intolerant to First-Line Second Generation Tyrosine Kinase Inhibitor (TKI) Treatment: An Interim Analysis of the Prospective PONS Trial

Free
Philipp le Coutre, Joachim R Göthert, Susanne Saussele, Uwe Pelzer, Lars Bullinger, Ahmet Elmaagacli, Christian Jehn, Frank Stegelmann, Andreas Hochhaus, Thomas Ernst, Andreas Burchert
Journal: Blood
Blood (2022) 140 (Supplement 1): 12202–12203.
https://doi.org/10.1182/blood-2022-162281
Published: 2022
Journal Articles

Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry

Free
Annamaria Brioli, Elza Lomaia, Christian Fabisch, Tomasz Sacha, Hana Klamová, Elena Morozova, Aleksandra Golos, Philipp Ernst, Ulla Olsson-Strömberg, Jiri Mayer, Franck E. Nicolini, Han Bao, Fausto Castagnetti, Elzbieta Patkowska, Klaus Hirschbühl, Edyta Paczkowska, Anne Parry, Astghik Voskanyan, Susanne Saussele, Georg-Nikolaus Franke, Alexander Kiani, Edgar Faber, Krzysztof Lewandowski, Stefan W. Krause, Elke Dammann, Peter Anhut, Justyna Gil, Thomas Südhoff, Sonja Heibl, Markus Pfirrmann, Andreas Hochhaus, Michael Lauseker
Journal: Blood
Blood (2022) 140 (Supplement 1): 818–820.
https://doi.org/10.1182/blood-2022-162252
Published: 2022
Journal Articles

Health-Related Quality of Life of CML Patients Under 2nd or 3rd Line Bosutinib Is Not Impaired Significantly By Gastrointestinal Toxicity (GI Tox) but Influenced By Sex - Results from a Subanalysis of the Bosutinib Dose Optimization (BODO) Study (CML-VII) Trial of the German CML Study Group

Free
Susanne Isfort, Dominik Wolf, Lino L. Teichmann, Martina Crysandt, Andreas Burchert, Andreas Hochhaus, Susanne Saussele, Alexander Kiani, Joachim R Göthert, Thomas Illmer, Philippe Schafhausen, Mareille Warnken-Uhlich, Uta Wolber, Denise Kohn, Kirsi Manz, Markus Pfirrmann, Tim H.H. Brummendorf
Journal: Blood
Blood (2022) 140 (Supplement 1): 12194–12196.
https://doi.org/10.1182/blood-2022-164607
Published: 2022
Journal Articles

ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase

Free
Thomas Ernst, Lioba Schönfeld, Jenny Rinke, Anna Hinze, Saskia N. Nagel, Vivien Schäfer, Thomas Schenk, Christian Fabisch, Tim H. Brümmendorf, Andreas Burchert, Philipp le Coutre, Stefan W. Krause, Susanne Saussele, Fatemeh Safizadeh, Markus Pfirrmann, Andreas Hochhaus
Journal: Blood
Blood (2022) 140 (Supplement 1): 807–808.
https://doi.org/10.1182/blood-2022-165041
Published: 2022
Journal Articles

Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)

Free
Katharina Kohlbrenner, Norbert Galuschek, Alice Fabarius, Marcel Reiser, Klaus Fenchel, Eva Eßeling, Thomas Göhler, Thomas Geer, Reinhard Depenbusch, Ivo Talah Azeh, Erik Engel, Richard Hansen, Hans-Walter Lindemann, Jürgen Anhuf, Paul Jehner, Maisun Abu-Samra, Markus Ritter, Norbert Gattermann, Henning Pelz, Stefan Fuxius, Burkhard Oswald, Gabriela M Baerlocher, Tim H.H. Brummendorf, Dominik Heim, Philipp le Coutre, Andreas Burchert, Dietger Niederwieser, Hans Tesch, Wolf-Karsten Hofmann, Andreas Hochhaus, Rüdiger Hehlmann, Susanne Saussele
Journal: Blood
Blood (2022) 140 (Supplement 1): 947–949.
https://doi.org/10.1182/blood-2022-159412
Published: 2022
Journal Articles

ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase

Free
Andreas Hochhaus, Susanne Saussele, Francois-Xavier Mahon, Virginia Pilipovic, Yifan Zhang, Peter Schuld, Tim H. Brümmendorf
Journal: Blood
Blood (2022) 140 (Supplement 1): 6787–6788.
https://doi.org/10.1182/blood-2022-163051
Published: 2022
Journal Articles

Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study

Free
Giovanni Zambrotta, Sarit Assouline, Franck E. Nicolini, Elisabetta Abruzzese, Maria Cristina Miggiano, Chiara Elena, Alberto Alvarez-Larran, Ana Triguero, Alessandra Iurlo, Cristina Bucelli, Francesca Lunghi, Isabella Capodanno, Margherita Maffioli, Sara Galimberti, Giovanni Caocci, Fabio Stagno, Susanne Saussele, Carmen Fava, Philipp le Coutre, Massimiliano Bonifacio, Veronica Guglielmana, Federica Colombo, Laura Antolini, Carlo Gambacorti-Passerini
Journal: Blood
Blood (2022) 140 (Supplement 1): 1504–1506.
https://doi.org/10.1182/blood-2022-162207
Published: 2022
Journal Articles

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Free
Andreas Burchert, Susanne Saussele, Christian Michel, Stephan K Metzelder, Andreas Hochhaus, Norbert Gattermann, Martina Crysandt, Philippe Schafhausen, Matthias Bormann, Markus P. Radsak, Agnès Guerci-Bresler, Thomas Illmer, Maria E Goebeler, Peter Herhaus, Lino L. Teichmann, Georg-Nikolaus Franke, Fabian Lang, Stefan W. Krause, Robert Möhle, Martine Klausmann, Frank Stegelmann, Christoph Lutz, Gabriel Etienne, Andrea Stoltefuß, Joachim R Göthert, Thomas Ernst, Andreas Neubauer, Rüdiger Hehlmann, Behnaz Aminossadati, Michael Wittenberg, Markus Pfirrmann, Carmen Schade-Brittinger, Philipp le Coutre, Franck E. Nicolini
Journal: Blood
Blood (2022) 140 (Supplement 1): 1501–1503.
https://doi.org/10.1182/blood-2022-169324
Published: 2022
Journal Articles

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Free
Clinical Trials & Observations
Delphine Réa, Michael J. Mauro, Carla Boquimpani, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Jane F. Apperley, Andre Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Koji Sasaki, Lynette Chee, Valentin García-Gutiérrez, Jorge E. Cortes, Paola Aimone, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Andreas Hochhaus
Journal: Blood
Blood (2021) 138 (21): 2031–2041.
https://doi.org/10.1182/blood.2020009984
Published: 2021
Includes: Supplemental data
Journal Articles

Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results

Free
Sarit Assouline, Maria Cristina Miggiano, Elisabetta Abruzzese, Chiara Elena, Giovanni Caocci, Susanne Saussele, Francesca Lunghi, Alberto Alvarez-Larran, Barbara Mora, Sigi Petrela, Laura Antolini, Carlo Gambacorti-Passerini, Alessandra Iurlo
Journal: Blood
Blood (2021) 138 (Supplement 1): 1476.
https://doi.org/10.1182/blood-2021-150496
Published: 2021
Journal Articles

Antibody Response to Vaccination with BNT162b2, mRNA-1273, and ChADOx1 in Patients with Myeloid and Lymphoid Neoplasms

Free
Jil Rotterdam, Margot Thiaucourt, Juliana Schwaab, Andreas Reiter, Sebastian Kreil, Laurenz Steiner, Henning D. Popp, Wolf-Karsten Hofmann, Karin Bonatz, Catharina Gerhards, Michael Neumaier, Mohamad Jawhar, Susanne Saussele
Journal: Blood
Blood (2021) 138 (Supplement 1): 218.
https://doi.org/10.1182/blood-2021-146832
Published: 2021
Journal Articles

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

Free
Michael J. Mauro, Yosuke Minami, Delphine Rea, Andreas Hochhaus, Elza Lomaia, Sergey Voloshin, Anna G. Turkina, Dong-Wook Kim, Jane F Apperley, Jorge E. Cortes, Andre N.R. Abdo, Laura Fogliatto, Dennis Dong Hwan Kim, Philipp D le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem A. Chaudhri, Lynette C.Y. Chee, Valentín Garcia Gutierrez, Koji Sasaki, Shruti Kapoor, Alex Allepuz, Sarah Quenet, Véronique Bédoucha, Carla Boquimpani
Journal: Blood
Blood (2021) 138 (Supplement 1): 310.
https://doi.org/10.1182/blood-2021-152561
Published: 2021